Measuring serum pepsinogen level of gastric cancer in Mongolian population

Abstract

Introduction: Mongolia has the highest mortality rate of gastric cancer (GC). Early detection and treatment can reduce the mortality of GC. Therefore, it is important to establish an efÏcient and better cost effective screening method for early detection of gastric cancer in regular mass survey. Purpose: The purpose of this study is to evaluate serum pepsinogen I, II and PGI / II in patients with gastric cancer in our country. Materials and methods: We investigated subjects with histologically proven adenocarcinoma who underwent GC-related operative treatment either at National Cancer Center in 2019-2020. In addition, relatively healthy people were age and gender adjustably selected from the department of endoscopy. In the two categories of the study, the PGI, PGII, PGI / II ratio screening test were performed by ELISA (enzyme linked immunosorbent assay) using the GastroPanel Elisa Kit from BIOHIT HealthCare, Finland and BIOBASE-EL10A reader album of Biobase Biodustry of China guidelines. Results: A total of 80 subjects (44 males, 36 females) were eligible for this study, and their mean age was 61.21 (±13.75) years. The mean serum PG I and PG II levels and PG I/II ratio were 78.76(±60.56), 17.45 (±13.14) µg/l, and 5.28(±4.18), respectively. The characteristics of the subjects without neoplasms and those with gastric neoplasms were compared; among the serological markers evaluated, the PG II level was not significantly different between the 2 groups (13.29± 5.98 vs 14.94±10.44 ng/mL, P=0.434). However, significant differences were found in the serum PG I level (68.11±35.39 vs 43.35±36.67 ng/mL, P<.009) and PG I/II ratio (5.49±2.83 vs 3.4 ±2.56, P<.004). Conclusion: The serum PGI and PGI / II ratios are decreasing in stomach cancer. ‑